EP1610776A4 - Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie - Google Patents

Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie

Info

Publication number
EP1610776A4
EP1610776A4 EP04758273A EP04758273A EP1610776A4 EP 1610776 A4 EP1610776 A4 EP 1610776A4 EP 04758273 A EP04758273 A EP 04758273A EP 04758273 A EP04758273 A EP 04758273A EP 1610776 A4 EP1610776 A4 EP 1610776A4
Authority
EP
European Patent Office
Prior art keywords
ocular hypertension
ophthalmic compositions
treating ocular
treating
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04758273A
Other languages
English (en)
French (fr)
Other versions
EP1610776A2 (de
Inventor
Michael H Fisher
Maria L Garcia
Gregory J Kaczorowski
Peter T Meinke
William H Parsons
Edward Andrew Boyd
Stephen Price
John Stibbard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec OAI
Merck and Co Inc
Original Assignee
Evotec OAI
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec OAI, Merck and Co Inc filed Critical Evotec OAI
Publication of EP1610776A2 publication Critical patent/EP1610776A2/de
Publication of EP1610776A4 publication Critical patent/EP1610776A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP04758273A 2003-03-27 2004-03-24 Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie Withdrawn EP1610776A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45810303P 2003-03-27 2003-03-27
PCT/US2004/009028 WO2004087051A2 (en) 2003-03-27 2004-03-24 Ophthalmic compositions for treating ocular hypertension

Publications (2)

Publication Number Publication Date
EP1610776A2 EP1610776A2 (de) 2006-01-04
EP1610776A4 true EP1610776A4 (de) 2007-03-28

Family

ID=33131753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04758273A Withdrawn EP1610776A4 (de) 2003-03-27 2004-03-24 Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie

Country Status (7)

Country Link
US (1) US7414067B2 (de)
EP (1) EP1610776A4 (de)
JP (1) JP2006524239A (de)
CN (1) CN1791402A (de)
AU (1) AU2004226479A1 (de)
CA (1) CA2519899A1 (de)
WO (1) WO2004087051A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067075A1 (en) * 2017-06-14 2018-12-20 European Molecular Biology Laboratory Bicyclic heteroaromatic amide compounds for use in therapy

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
US3338921A (en) * 1962-01-05 1967-08-29 Merck & Co Inc Thenoic and furoic acids
US3501465A (en) * 1964-07-02 1970-03-17 Merck & Co Inc 3-indolyl lower aliphatic amines
US3629284A (en) * 1965-04-19 1971-12-21 Sumitomo Chemical Co Process for the preparation of 3-indolyl aliphatic acid derivatives
EP0342682A2 (de) * 1988-05-19 1989-11-23 Warner-Lambert Company Hydroxamat-Derivate von nichtsteroidischen anti-inflammatorischen Acyl-Verbindungen, die Cyclooxygenase und 5-Lipoxygenase hemmen
WO1994021246A1 (en) * 1993-03-17 1994-09-29 Merck & Co., Inc. Use of non-steroidal antiinflammatory agents in macular degeneration
WO1996025397A1 (en) * 1995-02-15 1996-08-22 Merck Frosst Canada Inc. Indole derivatives with affinity for the cannabinoid receptor
WO2000040088A1 (en) * 1999-01-07 2000-07-13 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
WO2001052876A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2002065977A2 (en) * 2001-02-20 2002-08-29 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669960A (en) 1968-09-10 1972-06-13 Sumitomo Chemical Co Novel amides of 3-indolylacetic acid
IT7920398A0 (it) * 1979-02-21 1979-02-21 Resfar Srl Derivato ad attivita' analgesica antiinfiammatoria potenziata eprocedimento per la sua preparazione.
US4416890A (en) 1981-07-13 1983-11-22 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4386098A (en) 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4426388A (en) 1982-04-02 1984-01-17 Merck & Co., Inc. 5-Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4668697A (en) 1983-10-31 1987-05-26 Merck & Co., Inc. Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor
US4797413A (en) 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4824857A (en) 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
JP2844593B2 (ja) * 1987-05-28 1999-01-06 ソニー株式会社 受信装置
GB2209939B (en) 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
CA2164733A1 (en) 1993-06-08 1994-12-22 Nino Sorgente Methods and compositions for lowering intraocular pressure
AU680740B2 (en) 1994-02-22 1997-08-07 Merrell Pharmaceuticals Inc. Novel indole derivatives useful to treat estrogen-related neoplasms and disorders
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3338921A (en) * 1962-01-05 1967-08-29 Merck & Co Inc Thenoic and furoic acids
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
US3501465A (en) * 1964-07-02 1970-03-17 Merck & Co Inc 3-indolyl lower aliphatic amines
US3629284A (en) * 1965-04-19 1971-12-21 Sumitomo Chemical Co Process for the preparation of 3-indolyl aliphatic acid derivatives
EP0342682A2 (de) * 1988-05-19 1989-11-23 Warner-Lambert Company Hydroxamat-Derivate von nichtsteroidischen anti-inflammatorischen Acyl-Verbindungen, die Cyclooxygenase und 5-Lipoxygenase hemmen
WO1994021246A1 (en) * 1993-03-17 1994-09-29 Merck & Co., Inc. Use of non-steroidal antiinflammatory agents in macular degeneration
WO1996025397A1 (en) * 1995-02-15 1996-08-22 Merck Frosst Canada Inc. Indole derivatives with affinity for the cannabinoid receptor
WO2000040088A1 (en) * 1999-01-07 2000-07-13 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
WO2001052876A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2002065977A2 (en) * 2001-02-20 2002-08-29 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOLTZE K-H ET AL: "CHEMISCHE STRUKTUR UND ANTIPHLOGISTISCHE WIRKUNG IN DER REIHE DER SUBSTITUIERTEN INDOL-3-ESSIGSAEUREN CHEMICAL STRUCTURE AND ANTIINFLAMMATORY ACTIVITY IN THE GROUP OF SUBSTITUTED INDOLE-3-ACETIC ACIDS", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 30, no. 8A, 1980, pages 1314 - 1325, XP008055748, ISSN: 0004-4172 *
G. LINARI: "substituted anilides of 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-indole-3-acetic acid.", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH., vol. 23, no. 1, 1973, DEECV EDITIO CANTOR VERLAG, AULENDORF., pages 89 - 91, XP002413371 *

Also Published As

Publication number Publication date
JP2006524239A (ja) 2006-10-26
WO2004087051A3 (en) 2005-07-21
AU2004226479A1 (en) 2004-10-14
CN1791402A (zh) 2006-06-21
EP1610776A2 (de) 2006-01-04
US7414067B2 (en) 2008-08-19
WO2004087051A2 (en) 2004-10-14
CA2519899A1 (en) 2004-10-14
US20060069256A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
EP1646614A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1666027A4 (de) Ophthalmische zusammensetzung für kontaktlinse
EP1657265A4 (de) Neue beschichtungszusammensetzung
EP1961399A4 (de) Instrument zum einführen einer intraokularlinse
EP1934648A4 (de) Ophthalmisches linsenelement zur korrektur von kurzsichtigkeit
MA29098B1 (fr) Compositions pour le traitement du vhc
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1864181A4 (de) Beschichtungen für augenoptische linsenelemente
EP1664011A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
PL377172A1 (pl) Kompozycje do oczu do leczenia nadciśnienia śródgałkowego
EP1874256A4 (de) Hilfsrahmen für wirbelsäulenoperationen
EP1581503A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
EP1515722A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
GB0419174D0 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
FR2838635B1 (fr) Etui cosmetique pour une prothese endosquelletique.
EP2032130A4 (de) Ophthalmische zusammensetzungen zur behandlung von augenhochdruck
EP1515721A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
FR2860427B1 (fr) Insert humeral pour une prothese d'epaule inversee.
EP1662868A4 (de) Pflanzenschutz mittel und -verfahren
FR2862063B1 (fr) Agent gelifiant pour une huile
EP1915998A4 (de) Prophylaktisches oder therapeutisches mittel gegen hornhaut/bindehaut-erkrankungen
EP1771170A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
DE602004007920D1 (de) Waschmittelbehandlungzusammensetzungen
EP1663221A4 (de) Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20060123

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060123

Extension state: LT

Payment date: 20060123

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060123

Extension state: LT

Payment date: 20060123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20070109BHEP

Ipc: C07D 209/04 20060101ALI20070109BHEP

Ipc: A61K 31/404 20060101ALI20070109BHEP

Ipc: C07D 209/28 20060101AFI20070109BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070223

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STIBBARD, JOHN

Inventor name: PRICE, STEPHEN

Inventor name: BOYD, EDWARD ANDREW

Inventor name: PARSONS, WILLIAM, H.

Inventor name: MEINKE, PETER, T.

Inventor name: KACZOROWSKI, GREGORY, J.

Inventor name: GARCIA, MARIA, L.

Inventor name: FISHER, MICHAEL, H.

17Q First examination report despatched

Effective date: 20071106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090113